admin – Biopat

About admin

This author has not yet filled in any details.
So far admin has created 5 blog entries.

Diagnostic sub-classification of non-small cell lung cancer: Importance in clinical therapeutics and prognostication

M. J. Donovan, A. Kotsianti, A. Colomer, M. Verdú, M. Clayton, H. Pang, S. Hamann, C. Cordón-Cardó, X. Puig.

Background: The association of EGFR mutations with bronchoalveolar carcinoma (BAC) / non-small cell lung cancer (NSCLC) and the therapeutic and prognostic variability reported for lung cancer has reinforced the need for more accurate NSCLC sub-classification. The present […]

admin 2005-02-09T22:15:16+00:00

Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression

Erill N¹, Colomer A¹, Verdú M², Román R¹, Condom E¹, Hannaoui N³, Banús JM³, Cordón-Cardó C⁴, and Puig X ^1,2.

¹BIOPAT, Grup Assistència, Barcelona; ²HISTOPAT Laboratoris, Barcelona; ³ICUN, Barcelona; and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Altered p53 status is a frequent event in bladder cancer and reported to have prognostic significance. We […]

admin 2004-02-09T22:14:36+00:00

MSI status modulates the value of some molecular markers in colorectal tumors

A. Colomer, N. Erill, M. Verdú, R. Román, A Vidal, X. Puig.

BIOPAT. Biopatologia Molecular, SL. Barcelona, Spain.

LOH 17p/TP53 and LOH 18q/DCC have been related to prognosis of colorectal adenocarcinomas. Since MSI-H tumors have a minor rate of TP53 mutations and rarely present allelic deletions, we intended to study these molecular features in a series of 197 […]

admin 2002-02-09T22:12:42+00:00

TP53, 17P and 18Q alterations as prognostic markers in MSS colorectal adenocarcinomas

Anna Colomer¹, Nadina Erill¹, Montse Verdú², Ruth Román¹, August Vidal^1,2, Xavier Puig^1,2.

¹BIOPAT, Biopatologia Molecular, Barcelona, Spain. ²Histopat Laboratoris, Barcelona, Spain.

Two different patterns have been described for colorectal tumorigenesis. The main one -affecting 85% of sporadic tumors- is based on the familial adenomatous polyposis (FAP) model, a multistep process that involves at least APC, K-RAS, DCC andTP53 genes. […]

admin 2002-02-09T22:11:46+00:00

Marcadores de pronóstico en el carcinoma de mama

M. Guix Pericas ^1,2, C. Cordón Cardó ^1,2,3, M. A. Cañadas Bouzas ¹, A. Colomer Valero ², X. Puig Torrus ^1,2.

¹HISTOPAT S.A. Laboratoris. ²BIOPAT. Biopatologia molecular S.L. Grup Assistència. Barcelona. ³Memorial Sloan Kettering Cancer Center. Division of Molecular Pathology. Nueva York.

INTRODUCCIÓN

El carcinoma de mama es una de las neoplasias malignas más frecuentes y una de […]

admin 1998-02-09T22:13:49+00:00